Clinical Observation On The Treatment Of Sporotrichosis With10%Potassium Iodide Solution And Two Doses Of Terbinafine

Evaluate the clinical effects of10%solution of potassium iodide andTerbinafine of two doses in treating cutaneous sporotrichosis.Randomized Control Test. We randomly divide the patients who matchour standards into three groups: Group A, TBF250mg/d group, Terbinafine oraladministration250mg/d treatment group; Group B, Terbinafine oraladministration500mg/d treatment group; Group C,10%Potassium iodidesolution oral administration30m/d treatment group. The information of eachpatient is recorded with unified table. Comparatively analyze between groupson onset time, cure rate and treatment costs/effects. For measurement data thatconform to the normal distribution, select means±standard deviations todescribe the data; For measurement data that conform to skewed distribution,select median (the25-75th percentile) to describe the data. Group comparisonanalyses apply variance analysis or Kruskal-Wallis analysis. For enumerationdata apply Chi-square test or Fisher’s Exact Test.Course of Treatment: the median of TBF250mg/d group is3months; thatof TBF500mg/d group is2.5months; that of10%KI30ml/d group is2months.P=0.006. Onset Time: the median of TBF250group is9days; that ofTBF500mg/d group is9days; that of10%KI30ml/d is7days. P=0.046. CureRate: the cure rate in three months of TBF250mg/d is39.6%; that ofTBF500mg/d is70.7%; that of10%KI30mg/d is89.4%. P=0.004. The curerate in six months of TBF250mg/d is93.6%; that of TBF500mg/d is100%; thatof10%KI30ml/d is100%. P=0.104. Adverse Effects: adverse effects rate ofTBF250mg/d is12.2%; that of10%KI30ml/d is14.9%. P>0.05. Costs/Effects:the C/E values of TBF250mg/d group, TBF500mg/d group and10%KI30ml/dare23.36,39.38and6.04. This study reveals that10%solution of potassium iodide has definite andquick effect which makes it the first choice for patients with limited financialabilities. Compared with Terbinafine250mg/d,10%KI has quicker effect andshort course of treatment. Whilst the10%KI solution is safe to use, its metal’sbitter taste and liquid dosage-form cause discomfort for patients. Comparedwith Terbinafine500mg/d, Terbinafine250mg/d has significant advantage inCosts/Effects rate, though no significant differences in other aspects. Therefore,Terbinafine250mg/d is more suitable in developing countries like China,especially for patients most of whom are peasants with very limited financialabilities. This therapy can be the choice when there happens to be potassiumiodide and itraconazole intolerance or ineffectiveness.